EUVIMEDEUVIMED entdecken
Crossref

The role of antiphospholipid antibodies in recurrent pregnancy loss: a narrative review

Muthia Puspasari, Peby Maulina Lestari, M. Husni Amantubillah, M. Al Farisi Sutrisno

Intisari Sains Medis · 09.11.2026 · 17 (3)

DOI: 10.15562/ism.v17i3.2841 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Intisari Sains Medis, online erschienen am 09.11.2026. Verfasst von Muthia Puspasari und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Recurrent pregnancy loss (RPL) is a multifactorial reproductive disorder. Antiphospholipid syndrome (APS), characterized by persistent antiphospholipid antibodies (aPL), is one of the few established and treatable causes of RPL. This review examined current evidence on the role of aPL in RPL, covering pathogenesis, diagnosis, and treatment.

Methods

We conducted a narrative review using PubMed, Embase, and the Cochrane Library. We searched for systematic reviews, original studies, and clinical recommendations on RPL, APS, aPL, pathogenesis, diagnosis, and treatment.

Results

Antiphospholipid antibodies contribute to pregnancy morbidity through trophoblast dysfunction, inflammation, complement activation, and placental vascular injury, resulting in placental insufficiency and pregnancy loss. Lupus anticoagulant has the strongest association with pregnancy morbidity, whereas persistent moderate-to-high antibody titers and triple positivity indicate a high-risk aPL profile. APS assessment relies on clinical findings and laboratory results. The 2023 ACR/EULAR criteria offer an updated framework for classifying APS. In women with obstetric APS, low-dose aspirin combined with heparin remains the main evidence-based treatment and is associated with improved live birth outcomes.

Conclusion

Evaluation for APS is warranted in women with RPL because identifying clinically significant aPL profiles can support risk stratification and targeted treatment. Current evidence supports low-dose aspirin combined with heparin in appropriately selected women with obstetric APS. Further research is needed to clarify the management of non-criteria and low-titer aPL positivity.

Zitieren

APA

Puspasari, M., Lestari, P. M., Amantubillah, M. H., & Sutrisno, M. A. F. (2026). The role of antiphospholipid antibodies in recurrent pregnancy loss: a narrative review. Intisari Sains Medis, 17(3). https://doi.org/10.15562/ism.v17i3.2841

Vancouver

Puspasari M, Lestari PM, Amantubillah MH, Sutrisno MAF. The role of antiphospholipid antibodies in recurrent pregnancy loss: a narrative review. Intisari Sains Medis. 2026;17(3). doi:10.15562/ism.v17i3.2841

BibTeX
@article{Puspasari2026,
  author = {Puspasari, Muthia and Lestari, Peby Maulina and Amantubillah, M. Husni and Sutrisno, M. Al Farisi},
  title = {The role of antiphospholipid antibodies in recurrent pregnancy loss: a narrative review},
  journal = {Intisari Sains Medis},
  year = {2026},
  volume = {17},
  number = {3},
  doi = {10.15562/ism.v17i3.2841}
}
Kostenlos starten →